In recent market news, CG Oncology (CGON, Financial) has caught the attention of investors following a significant update from JP Morgan. On May 2, 2025, JP Morgan announced the initiation of coverage on CGON with an "Overweight" rating, a positive outlook considering the company's current market position.
The analyst behind this coverage, Brian Cheng, has set a price target of USD 41.00 for CGON. This target highlights JP Morgan's confidence in CG Oncology's potential for growth, reflecting an optimistic stance in the biopharmaceutical sector.
This initiation of coverage is a critical development for CGON as it can influence investor sentiment and potentially impact the stock's performance in the market. Stakeholders and potential investors will be keeping a close watch on CGON to see how the market reacts to this new price target and analyst rating.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for CG Oncology Inc (CGON, Financial) is $62.63 with a high estimate of $82.00 and a low estimate of $23.00. The average target implies an upside of 125.76% from the current price of $27.74. More detailed estimate data can be found on the CG Oncology Inc (CGON) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, CG Oncology Inc's (CGON, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
